Pfizer has agreed to pay $59.7m to resolve illegal payments to healthcare professionals made by Biohaven Pharmaceuticals, a biopharma it acquired over two years ago. The charges allege that ...

Not content with a $1.2 billion licensing deal for Biohaven Pharma's oral migraine therapy rimegepant, Pfizer has just offered to buy the company outright – for a cool $11.6 billion. Pfizer's ...

Pfizer (NYSE:PFE) has agreed to pay nearly $60M to resolve allegations that its Biohaven unit paid kickbacks to physicians to induce prescriptions for its migraine drug Nurtec ODT.

Pharmaceutical giant Pfizer Inc. on Monday completed its $11.6 billion acquisition of New Haven’s Biohaven Pharmaceutical Holding Company Ltd., maker of migraine drug Nurtec ODT. The deal gives ...

A new, slimmed-down Biohaven issued its debut earnings release post-Pfizer split, touting a $301.9 million fundraising, new executive staffers and a pipeline stocked with therapies to test in ...

The scheme took place from March 1, 2020, through Sept. 30, 2022. Pfizer bought Biohaven in October 2022. PFIZER'S PAXLOVID FAILS AS 15-DAY TREATMENT FOR LONG COVID, STUDY FINDS Prosecutors said ...

Pfizer acquired Nurtec ODT as part of the company's acquisition of Biohaven Pharmaceuticals in October 2022. Pfizer is working to develop new packaging for Nurtec ODT "as a long-term solution." ...

Pfizer ended the Nurtec speaker programs after paying $11.5 billion to buy Biohaven in October 2022. "Patients deserve to know that their doctor is prescribing medications based on their doctor's ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter ...

Pfizer subsidiary Biohaven allegedly gave physicians speaker honoraria and meals at high-end restaurants to induce them to prescribe Nurtec. A complete guide to lease accounting for healthcare ...

Pfizer Inc's PFE subsidiary Biohaven Ltd BHVN released an updated investor presentation with additional data on the company's BHV-1300 program, a potential competitor to FcRn-targeting ...